2023
Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations
Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan B, Pal S. Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations. The Oncologist 2023, 28: s9-s10. PMCID: PMC10445590, DOI: 10.1093/oncolo/oyad216.014.Peer-Reviewed Original ResearchDisease control rateFirst-line ICIImmune checkpoint inhibitorsOverall survivalTime of presentationSynchronous diseaseTreatment failureRenal cell carcinomaMetachronous diseaseMetastatic diseaseRCC diagnosisFirst-line immune checkpoint inhibitorsMetastatic renal cell carcinoma patientsMultivariable Cox proportional hazards modelsLower disease control rateNon-clear cell histologyMetastatic renal cell carcinomaRenal cell carcinoma patientsCox proportional hazards modelIMDC risk scoresInitial RCC diagnosisSynchronous metastatic diseaseMedian overall survivalMedian TTFFirst-line treatment
2022
First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Roussel E, Kinget L, Beuselinck B, Albersen M, Wells C, Ernst M, Donskov F, Schmidt A, Szabados B, Pal S, Meza L, Agarwal N, Weickhardt A, Davis I, Alva A, Wood L, Porta C, Choueiri T, Heng D, Navani V. First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 317-317. DOI: 10.1200/jco.2022.40.6_suppl.317.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumMetastatic renal cell carcinomaPancreatic metastasisOverall survivalVascular endothelial growth factorRenal cell carcinomaMedian OSCell carcinomaInternational Metastatic Renal Cell Carcinoma Database Consortium risk groupMetastatic renal cell carcinoma patientsMedian OS of patientsRetrospective analysis of patientsEfficacy of first-lineKaplan Meier survival curvesOS of patientsSite of metastasisFirst-line therapyAssociated with improved outcomesIndolent biological behaviorAnalysis of patientsAnti-angiogenic therapyVEGF monotherapyEndothelial growth factorLow event ratesImproved OS
2019
Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma
Bergerot P, Bergerot C, Philip E, Meza L, Dizman N, Hsu J, Pal S. Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma. Kidney Cancer 2019, 3: 63-70. DOI: 10.3233/kca-180047.Peer-Reviewed Original ResearchVascular endothelial growth factor tyrosine kinase inhibitorHigher body mass indexBody mass indexLower body mass indexMedian overall survivalOverall survivalMass indexMetastatic renal cell carcinoma patientsMetastatic renal cell carcinomaEffect of BMIRenal cell carcinoma patientsImproved overall survivalCell carcinoma patientsBetter overall survivalKaplan-Meier methodContext of immunotherapyRenal cell carcinomaPatients 66Median OSCarcinoma patientsClinical outcomesHigher BMIRetrospective studyCell carcinomaClinical variables